Does the CYTK Form 4 show any derivative exercises or tax-related share sales?

The Form 4 reports no option exercises, tax withholding dispositions, or sales. It only records two acquisition transactions: a direct grant of 2,851 Common Stock shares and a grant of a non-qualified stock option covering 4,301 underlying Common Stock shares.

CYTOKINETICS director receives stock, option awards

CYTOKINETICS INC director Edward M. Kaye, MD received new equity compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC director Edward M. Kaye, MD received new equity compensation. He was granted 2,851 shares of Common Stock and now directly holds 13,216 shares. He also received a non-qualified stock option for 4,301 shares at an exercise price of $77.15 per share, exercisable beginning on June 27, 2026 and expiring on May 26, 2036.

Insider Trade Summary

Grant/Award: 7,152 shares

Grant/Award 2 txns

Insider Kaye Edward M. MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	$0.00
Grant/Award	Common Stock	2,851	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 contracts (Direct); Common Stock — 13,216 shares (Direct)

Key Figures

Common Stock grant: 2,851 shares Shares held after grant: 13,216 shares Option grant size: 4,301 shares +3 more

6 metrics

Common Stock grant 2,851 shares Director stock award on May 27, 2026

Shares held after grant 13,216 shares Direct Common Stock holdings following transaction

Option grant size 4,301 shares Non-qualified stock option covering Common Stock

Option exercise price $77.15 per share Non-qualified stock option strike price

Option first exercisable date June 27, 2026 Earliest exercise date for stock option

Option expiration date May 26, 2036 Expiration of non-qualified stock option

Key Terms

Non-Qualified Stock Option (Right to Buy), grant/award acquisition, exercise price, Common Stock

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition" for both transactions"

exercise price financial

"conversion_or_exercise_price: "77.1500" for the stock option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"security_title: "Common Stock" and underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CYTK director Edward M. Kaye report?

Edward M. Kaye reported equity awards, not market trades. He received 2,851 shares of CYTOKINETICS INC Common Stock and a non-qualified stock option for 4,301 underlying shares, both characterized as grant or award acquisitions as part of his director compensation.

How many CYTOKINETICS (CYTK) shares does Edward M. Kaye hold after this Form 4?

After the reported grant, Edward M. Kaye directly holds 13,216 shares of CYTOKINETICS INC Common Stock. This figure reflects his updated direct non-derivative ownership position following receipt of the 2,851-share stock award disclosed in the Form 4 filing.

What are the key terms of Edward M. Kaye’s CYTK stock option grant?

Kaye received a non-qualified stock option for 4,301 CYTOKINETICS INC shares at an exercise price of $77.15 per share. The option becomes exercisable on June 27, 2026 and expires on May 26, 2036, providing long-term potential equity exposure.

Was Edward M. Kaye buying or selling CYTOKINETICS (CYTK) stock on the open market?

The Form 4 shows no open-market buying or selling. Instead, Edward M. Kaye acquired shares and options through compensation awards coded as grants, with a zero dollar transaction price, indicating non-cash equity compensation rather than market purchases or sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/27/2026 - 07:11 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/27/2026		A		2,851	A	$0	13,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/27/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR